MB-07803

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C24H37N4O7PS
Molecular Weight	556.612
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCOC(=O)C(C)(C)NP(=O)(NC(C)(C)C(=O)OCC)C1=CC=C(O1)C2=C(SC(N)=N2)C(=O)C(C)(C)C

InChI

InChIKey=CTKZZUXRWBCFEI-UHFFFAOYSA-N

InChI=1S/C24H37N4O7PS/c1-10-33-19(30)23(6,7)27-36(32,28-24(8,9)20(31)34-11-2)15-13-12-14(35-15)16-17(37-21(25)26-16)18(29)22(3,4)5/h12-13H,10-11H2,1-9H3,(H2,25,26)(H2,27,28,32)

HIDE SMILES / InChI

Description
Sources: https://www.vikingtherapeutics.com/pipeline/other-pipeline-programs/ | https://adisinsight.springer.com/drugs/800021139

MB-07803 (VK-0612) is a potent inhibitor of fructose-1,6-bisphosphatase (FBPase). Inhibition of FBPase is an effective mechanism for lowering fasting and postprandial hyperglycemia in patients with poorly-controlled Type 2 diabetes. Viking Therapeutics is developing MB-07803 for the treatment of type 2 diabetes.

Originator

Approval Year

PubMed

Title	Date	PubMed
Fructose-1, 6-bisphosphatase inhibitors for reducing excessive endogenous glucose production in type 2 diabetes.	2011	21484576

Sample Use Guides

In Vivo Use Guide

he Phase 2a proof‐of‐concept trial was conducted in patients with moderate to severe type 2 diabetes. In this trial, patients received either placebo or MB-07803 (VK-0612) (10, 50, 100 or 200 mg capsule) once-daily for 28 days.

Route of Administration: Oral

Name

Type

Language

MB-07803

Common Name

English

MB 07803

Preferred Name

English

MB07803

Common Name

English

ALANINE, N,N'-((5-(2-AMINO-5-(2,2-DIMETHYL-1-OXOPROPYL)-4-THIAZOLYL)-2-FURANYL)PHOSPHINYLIDENE)BIS(2-METHYL-, DIETHYL ESTER

Common Name

English

ALANINE, N,N'-((5-(2-AMINO-5-(2,2-DIMETHYL-1-OXOPROPYL)-4-THIAZOLYL)-2-FURANYL)PHOSPHINYLIDENE)BIS(2-METHYL-, 1,1''-DIETHYL ESTER

Common Name

English

Code System Code Type Description

FDA UNII

GG81XF45C2